AI is transforming oncology by improving early detection, diagnosis, and treatment personalization through advanced data ...
Oncology pharmacists bridge gaps in test ordering, result interpretation, and therapy access, ensuring timely and effective ...
The U.S. Food and Drug Administration (FDA) has accepted a new drug application for gedatolisib in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA ...
Combination therapies represent a promising frontier in cancer treatment, addressing the critical need to enhance efficacy while minimizing resistance. By combining different therapeutic agents and ...
New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia ...
Flow Space on MSN
This CEO Lost Family to Cancer. Now, He's Banking on Radically Transforming Early Detection of Breast Cancer
"If we've made a dent in alleviating fear, we've done our job." ...
Protocol-Stipulated Dose Modification to Manage Chemotherapy-Induced Peripheral Neuropathy in Children, Adolescents, and Young Adults With High-Risk Hodgkin Lymphoma We conducted a retrospective ...
The FDA has accepted a New Drug Application (NDA) for Celcuity’s gedatolisib in hormone receptor positive (HR+), human ...
A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene ...
Pelareorep combined with atezolizumab achieved a 29% ORR in heavily pretreated metastatic SCAC patients, significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback